Ultragenyx Pharmaceutical (RARE)
NASDAQ:RARE
Want to see RARE full AI Analyst Report?
Earnings Data
Report Date
Jul 30, 2026TBA (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
-1.23Last Year’s EPS
-1.17Same Quarter Last Year
Strong Buy
Based on 15 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call balances strong commercial execution, clear revenue guidance (reaffirmed $730M–$760M for 2026), rapid pipeline progress (two near-term PDUFAs and promising long-term GTX-102 data with Bayley-4 and MDRI signals), and manufacturing/launch readiness against meaningful near-term financial pressure (Q1 net loss of $185M, $197M cash used in operations, high operating expenses and restructuring charges). Management presented a credible path to profitability in 2027 with planned R&D/SG&A reductions and assumed PRV monetization, but timing uncertainty for Phase 3 readouts, quarter-to-quarter ordering variability and execution risks around launches and PRV realization remain. Overall the positives around product performance, global commercialization scale, and upcoming catalysts outweigh the near-term financial and execution risks.Company Guidance
Total Revenue and Product Contributions (Q1 2026)
Total revenue of $136 million in Q1 2026. Product contributions: Crysvita $93M (North America $39M, Latin America & Turkey $46M, Europe $8M), Dojolvi $18M, Evkeeza $18M, Mepsevii $7M.
Year Guidance Reaffirmed (2026)
Reaffirmed 2026 revenue guidance of $730M–$760M, representing 8%–13% growth over 2025 (guidance excludes potential revenue from new product launches).
Strong Evkeeza Growth
Evkeeza Q1 revenue of $18M, representing 64% growth versus Q1 2025, driven by international launches and expanding access across territories.
Commercial Scale and Patient Reach
Commercial presence in more than 35 countries. Crysvita: ~30 new patients started in Q1 in Latin America bringing that region to >950 patients. Dojolvi: >675 reimbursed patients in North America and ~300 in Europe (named/early access). Evkeeza: ~370 patients across 18 countries.
Pipeline Milestones and Upcoming Regulatory Catalysts
Two near-term PDUFA dates: DTX401 (Aug 23, 2026; no advisory committee planned) and UX111 (Sep 19, 2026). GTX-102 Aspire Phase 3 top-line readout expected in second half of 2026; Aurora study enrollment progressing to expand ages/genotypes.
Promising GTX-102 Phase 1/2 Long-Term Data
Phase 1/2 program: 74 patients treated, 66 in long-term extension (avg ~3 years on therapy, some ~5 years). Bayley-4 Cognitive raw score at month 12: mean change ~10 points (exceeds meaningful difference of 6 points). Multi-domain Responder Index (MDRI) p-value < 0.0001 at months 12/24/36. No new cases of transient lower extremity weakness reported; favorable long-term safety profile.
Manufacturing and Launch Readiness
Gene therapy manufacturing ramp-up underway: Bedford, MA facility producing drug substance/product for DTX401 and fill/finish for UX111; inventory being built in advance of potential launches to support commercial readiness.
Cost Discipline and Multi-Year Expense Outlook
Reaffirmed R&D and SG&A guidance: combined R&D and SG&A expected to be flat to down low-single-digits versus 2025 for 2026; expecting at least a 15% decrease in combined R&D and SG&A in 2027 versus 2025.
PRV Monetization Assumptions
Company plans to monetize two Priority Review Vouchers (expected to be monetized at ~>$100M each in current modeling) for 111 and 401; potential additional PRV from 102 is upside.
Cash Position and Context
Cash, cash equivalents and marketable securities of $534M as of March 31, 2026; management notes Q1 typically shows higher operating cash use due to annual bonus payouts and some one-time payments.
RARE Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
RARE Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 05, 2026 | $25.01 | $25.93 | +3.68% |
Feb 12, 2026 | $23.50 | $20.52 | -12.68% |
Nov 04, 2025 | $32.46 | $31.87 | -1.82% |
Aug 05, 2025 | $28.92 | $28.05 | -3.01% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Ultragenyx Pharmaceutical (RARE) report earnings?
Ultragenyx Pharmaceutical (RARE) is schdueled to report earning on Jul 30, 2026, TBA (Confirmed).
What is Ultragenyx Pharmaceutical (RARE) earnings time?
Ultragenyx Pharmaceutical (RARE) earnings time is at Jul 30, 2026, TBA (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is RARE EPS forecast?
RARE EPS forecast for the fiscal quarter 2026 (Q2) is -1.23.